Dupilumab‐associated ocular surface disease or atopic keratoconjunctivitis not improved by dupilumab? Upadacitinib may clarify the dilemma: A case report

• Autors principals: Marco Galluzzo (Autor), Lorenzo Tofani (Autor), Sara Spelta (Autor), Marina Talamonti (Autor), Alessandra Micera (Autor), Luca Bianchi (Autor), Marco Coassin (Autor), Stefano Bonini (Autor), Antonio Di Zazzo (Autor)
• Format: Llibre
• Publicat: Wiley, 2024-06-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Abstract Dupilumab‐associated ocular surface disease is a common clinical sign appearing in patients with atopic dermatitis (AD) just few months after dupilumab treatment start, developing in about 25% of patients. Atopic keratoconjunctivitis (AKC) is a well‐identified clinical entity, defined as a...